Wegovy and Zepbound are certain to be top sellers if the federal drug marketplace is launched. The two medications, and others, are set to be priced very advantageously.
After a rapid rise, Eli Lilly needs only an 11% gain to hit $1 trillion in market value. Revenue is expected to rise 26% next year, helped by its weight-loss products.
The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rate both quantitatively and qualitatively and select the top 10 names from an initial list of nearly 400 dividend stocks. The final list of ten stocks is chosen based on sector diversity, high-growth...
The world's most valuable healthcare stock, Eli Lilly and Company NYSE: LLY, just dropped huge news. Like Pfizer NYSE: PFE, Lilly announced a drug pricing deal with the Trump Administration.
Blood-thinning drugs that doctors often prescribe interchangeably after procedures to reopen narrowed heart arteries don't work equally well in patients with diabetes, a study from India found.
Eli Lilly is poised to become the first $1 trillion pharmaceutical company, driven by explosive growth in its weight-loss drug, Mounjaro. LLY's earnings and sales growth have been exceptional, with quarterly earnings up 495% and sales up 38% year-over-year, outpacing industry peers. The stock boasts a stellar long-term performance record, outperforming the S&P 500 and earning top momentum and p...
Novo Nordisk and Eli Lilly do not have a weight-loss drug partnership with telehealth website Mangoceuticals Inc , spokespeople for both companies said, rejecting a press release issued by the company on Thursday that described arrangements with the two leading drugmakers.
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.